Cinclus Pharma receives approval of the International Nonproprietary Name (INN) linaprazan glurate for its lead drug candidate for the treatment of GERD
Stockholm, Sweden: Cinclus Pharma Holding AB (“Cinclus Pharma”), a biopharmaceutical company focused on the development of a novel treatment for severe gastroesophageal reflux disease (“GERD”), today announced that the World Health Organization (WHO) has designated linaprazan glurate as the International Nonproprietary Name (INN) for its lead drug candidate, formerly known as X842.Linaprazan glurate is a prodrug of the P-CAB linaprazan, developed originally by AstraZeneca in Sweden. Linaprazan was evaluated in 23 phase I, and two phase II studies respectively, including approximately 2,500